CA3052713A1 - Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders - Google Patents

Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders Download PDF

Info

Publication number
CA3052713A1
CA3052713A1 CA3052713A CA3052713A CA3052713A1 CA 3052713 A1 CA3052713 A1 CA 3052713A1 CA 3052713 A CA3052713 A CA 3052713A CA 3052713 A CA3052713 A CA 3052713A CA 3052713 A1 CA3052713 A1 CA 3052713A1
Authority
CA
Canada
Prior art keywords
ipolamiide
production
extract
compounds
vegetal biomass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3052713A
Other languages
English (en)
French (fr)
Inventor
Cristiano Ruch Werneck Guimaraes
Carlos Eduardo VITOR
Lisandra Ravanelli PESSA
Romulo Dragani REIS
Alessandra MASCARELLO
Fernando Henrique De Souza GAMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ache Laboratorios Farmaceuticos SA
Original Assignee
Ache Laboratorios Farmaceuticos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos SA filed Critical Ache Laboratorios Farmaceuticos SA
Publication of CA3052713A1 publication Critical patent/CA3052713A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/92—Unsaturated compounds containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
CA3052713A 2017-02-17 2018-02-19 Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders Pending CA3052713A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102017003318-0A BR102017003318A2 (pt) 2017-02-17 2017-02-17 compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
BRBR1020170033180 2017-02-17
PCT/BR2018/050037 WO2018148816A2 (en) 2017-02-17 2018-02-19 Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3259255A Division CA3259255A1 (en) 2017-02-17 2018-02-19 Ipolamiide derivativres and plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders

Publications (1)

Publication Number Publication Date
CA3052713A1 true CA3052713A1 (en) 2018-08-23

Family

ID=61282932

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3052713A Pending CA3052713A1 (en) 2017-02-17 2018-02-19 Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders
CA3259255A Pending CA3259255A1 (en) 2017-02-17 2018-02-19 Ipolamiide derivativres and plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3259255A Pending CA3259255A1 (en) 2017-02-17 2018-02-19 Ipolamiide derivativres and plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders

Country Status (28)

Country Link
US (1) US12698265B2 (cg-RX-API-DMAC7.html)
EP (2) EP3583103B1 (cg-RX-API-DMAC7.html)
JP (2) JP7349362B2 (cg-RX-API-DMAC7.html)
KR (2) KR102882868B1 (cg-RX-API-DMAC7.html)
CN (1) CN110475768B (cg-RX-API-DMAC7.html)
AU (2) AU2018221956B2 (cg-RX-API-DMAC7.html)
BR (1) BR102017003318A2 (cg-RX-API-DMAC7.html)
CA (2) CA3052713A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002309A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019008891A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125187T1 (cg-RX-API-DMAC7.html)
DK (1) DK3583103T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP19058322A (cg-RX-API-DMAC7.html)
ES (1) ES2909387T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220377T1 (cg-RX-API-DMAC7.html)
IL (2) IL268732B2 (cg-RX-API-DMAC7.html)
LT (1) LT3583103T (cg-RX-API-DMAC7.html)
MX (2) MX2019009655A (cg-RX-API-DMAC7.html)
PE (2) PE20242300A1 (cg-RX-API-DMAC7.html)
PL (1) PL3583103T3 (cg-RX-API-DMAC7.html)
PT (1) PT3583103T (cg-RX-API-DMAC7.html)
RS (1) RS63162B1 (cg-RX-API-DMAC7.html)
SA (1) SA519402443B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907375VA (cg-RX-API-DMAC7.html)
SI (1) SI3583103T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200121T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018148816A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201906106B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
CN115304652A (zh) * 2022-07-25 2022-11-08 福建华闽晟业生物科技有限公司 一种利用巨菌草制备野芝麻新甙的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703543A (en) * 1969-11-05 1972-11-21 American Home Prod Hydroxamic acids of alicyclic amino acids
IL57433A (en) * 1978-06-03 1982-08-31 Inst Rech Chim Biolog Pharmaceutical compositions containing cyclopentane derivatives
DE3030477C2 (de) * 1980-08-12 1986-10-16 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Iridoid-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung
JPH0366682A (ja) * 1989-08-04 1991-03-22 Tsumura & Co 新規イリドイド誘導体
AU651849B2 (en) * 1990-10-09 1994-08-04 Tsumura & Co. Iridoid derivatives and their use as medicines
DE19644422C2 (de) 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
EP1145709A1 (de) * 2000-04-14 2001-10-17 Laboratoires Serobiologiques Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen
DE60336549D1 (de) * 2002-05-10 2011-05-12 Council Scient Ind Res Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure
EP1371372A1 (de) * 2002-06-08 2003-12-17 Cognis Iberia, S.L. Verwendung von Wirkstoffgemischen enthaltend Tocopherole und Extrakte des Harpagophytum procumbens zur Herstellung eines Medikamentes gegen rheumatische Arthritis
US7501222B2 (en) * 2005-06-24 2009-03-10 Dongjin Semichem Co., Ltd. Photoresist monomer polymer thereof and photoresist composition including the same
JP2008024670A (ja) * 2006-07-24 2008-02-07 Daiwa Kagaku Kogyo Kk 害虫駆除剤
US8552210B2 (en) * 2006-12-21 2013-10-08 E I Du Pont De Nemours And Company Hydrogenation of catmint oil
BRPI0700767B8 (pt) 2007-02-15 2021-05-25 Ache Laboratorios Farmaceuticos Sa composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo
KR101406933B1 (ko) * 2011-09-02 2014-06-12 동국대학교 산학협력단 라카아제를 이용한 새로운 효소형 시간-온도 이력지시계
CN103120699B (zh) * 2011-11-18 2017-04-19 天津市国际生物医药联合研究院 环烯醚萜类化合物在制备抗sars的药物中的应用
CN103690551A (zh) * 2013-07-18 2014-04-02 江苏大学 猪殃殃中环烯醚萜苷提取物及其提取方法和医药用途
DE102015102020A1 (de) * 2015-02-12 2016-08-18 Renate Wilmanowicz Immunologisch aktives Phyto-Gemisch und seine Anwendung bei der Prävention und in einem Verfahren zur Behandlung von Effloreszenzen
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas

Also Published As

Publication number Publication date
JP2023061959A (ja) 2023-05-02
CO2019008891A2 (es) 2020-01-17
CN110475768A (zh) 2019-11-19
IL268732B2 (en) 2024-12-01
SMT202200121T1 (it) 2022-07-21
PE20242300A1 (es) 2024-12-11
CL2019002309A1 (es) 2020-05-29
CY1125187T1 (el) 2023-06-09
BR112019017128A2 (pt) 2020-04-14
EP3583103A2 (en) 2019-12-25
IL268732B1 (en) 2024-08-01
AU2018221956A1 (en) 2019-08-29
AU2022201835A1 (en) 2022-04-07
US20200231561A1 (en) 2020-07-23
IL313974A (en) 2024-08-01
JP7349362B2 (ja) 2023-09-22
KR20250145126A (ko) 2025-10-13
BR102017003318A2 (pt) 2018-10-30
ES2909387T3 (es) 2022-05-06
RU2019129095A3 (cg-RX-API-DMAC7.html) 2021-10-27
JP7685540B2 (ja) 2025-05-29
RU2019129095A (ru) 2021-03-17
AU2018221956B2 (en) 2022-03-24
EP3583103B1 (en) 2022-01-12
EP4001270A1 (en) 2022-05-25
KR102882868B1 (ko) 2025-11-07
JP2020507607A (ja) 2020-03-12
RS63162B1 (sr) 2022-05-31
DK3583103T3 (da) 2022-03-14
SG11201907375VA (en) 2019-09-27
SA519402443B1 (ar) 2023-02-08
AU2022201835B2 (en) 2024-05-30
PL3583103T3 (pl) 2022-08-01
MX2022012282A (es) 2022-10-27
KR20190121790A (ko) 2019-10-28
WO2018148816A3 (en) 2018-10-18
PT3583103T (pt) 2022-03-25
NZ756074A (en) 2025-10-31
HRP20220377T1 (hr) 2022-07-08
IL268732A (en) 2019-10-31
WO2018148816A4 (en) 2019-01-03
CA3259255A1 (en) 2025-04-04
WO2018148816A2 (en) 2018-08-23
US12698265B2 (en) 2026-08-04
MX2019009655A (es) 2020-07-24
ZA201906106B (en) 2020-08-26
PE20200449A1 (es) 2020-02-28
ZA202501840B (en) 2025-10-29
SI3583103T1 (sl) 2022-07-29
LT3583103T (lt) 2022-04-25
CN110475768B (zh) 2023-12-01
ECSP19058322A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
US10588885B2 (en) Chlorogenic acid composition and method for its use in the treatment of Alzheimer's disease
CN105814072B (zh) 一种五环三萜结构修饰化合物及其制备方法和应用
US20140322365A1 (en) Method for preventing or treating arthritis
JP7685540B2 (ja) 化合物、化合物の製造法、富化抽出物、富化抽出物の活性な分画、富化抽出物の製造法、富化抽出物を製造するため植物バイオマスを選択する方法、免疫障害を治療するための組成物とその利用
CN102186485B (zh) 含有络石藤干燥提取物的乙酸乙酯级分作为有效成分的炎症性疾病预防及治疗用药物组合物与所述级分的制备方法
Seo et al. Inhibitory effect of α-amyrin acetate isolated from Fraxinus rhynchophylla on Th17 polarization
HK40074103A (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders and vitiligo
CN103408528B (zh) 一种色满化合物及其制备方法和应用
RU2781809C2 (ru) Соединение, способ получения соединений, обогащенный экстракт, активные фракции обогащенного экстракта, способ получения обогащенного экстракта, способ отбора растительной биомассы для получения обогащенного экстракта, композиция и применение для лечения иммунологических нарушений
US20100173028A1 (en) Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same
KR101905853B1 (ko) Dna 단편 혼합물을 포함하는 아토피 피부염의 예방 또는 치료용 조성물
HK40011154B (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders
HK40011154A (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders
BR112019017128B1 (pt) Processo para produção de extrato enriquecido com derivados de ipolamida
JPH1045613A (ja) インターロイキン4産生抑制剤
BR122025011688A2 (pt) Compostos de fórmula (ii), uso de compostos de fórmula (ii), composição farmacêutica, processo para produção de extrato enriquecido com derivados de ipolamida da fórmula (ii), extratos de plantas do gênero stachytarpheta e uso dos extratos de plantas do gênero stachytarpheta
CN103450142B (zh) 一种色满化合物及其提取方法和应用
CN107857754B (zh) 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用
CN105920152A (zh) 一种化橘红有效部位及其在制备治疗糖尿病心肌病的药物中的应用
BR122025011691A2 (pt) Uso de compostos de fórmula c

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220907

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250212

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250612

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250612

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260224